Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV
Clinical trial NCT05870475 · RECRUITING
Trial details
- NCT number
- NCT05870475
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-06-30
- Primary completion
- 2028-03-31
- Enrollment
- 94
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.